Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02253316
Other study ID # 201411060
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date January 20, 2015
Est. completion date August 31, 2024

Study information

Verified date July 2023
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to evaluate a treatment regimen called IRD which will be given to participants after their stem cell transplant in an effort to help prolong the amount of time the participants are disease-free after transplant. IRD is a three-drug regimen consisting of ixazomib, lenalidomide (also called Revlimid), and dexamethasone. After 4 cycles of IRD, the participants will be randomized to receive maintenance therapy either with ixazomib or lenalidomide.


Description:

Based on the further need to improve progression-free survival and overall survival post-autologous stem cell transplantation (ASCT) for multiple myeloma and the benefits seen of consolidation/maintenance treatment with immunomodulatory drugs thalidomide and lenalidomide and the proteasome inhibitor bortezomib, the natural next step is to evaluate combination regimens of immunomodulatory drugs and proteasome inhibitors as consolidation/maintenance post-ASCT. The regimen consisting of ixazomib, lenalidomide, and dexamethasone (IRD) has been shown to have low toxicity, and the availability of an oral formulation of ixazomib allows for easier administration when compared to bortezomib. In this study, following consolidation with IRD, patients will be randomized to maintenance therapy with lenalidomide or ixazomib in order to collect pilot data comparing the toxicity and efficacy of maintenance therapy with immunomodulatory drugs and proteasome inhibitors. 09/23/2019: Upon review of the interim analysis, there will be no further randomizations into the maintenance portion of the trial. All patients will be enrolled into the lenalidomide arm with the exception of those who discontinue lenalidomide during the consolidation phase due to toxicity. Patients who discontinue lenalidomide may be enrolled into the ixazomib arm following approval from the principal investigator. 09/30/2021: Following analysis 4 in 2021, analysis of the primary endpoint, all patients receiving lenalidomide maintenance will be transitioned off-study. Patients receiving ixazomib may remain on trial until disease progression or unacceptable toxicity at the discretion of the treating physician and the site principal investigator.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 236
Est. completion date August 31, 2024
Est. primary completion date February 5, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria Each patient must meet all of the following inclusion criteria to begin IRD Consolidation: - Between the ages of 18 and 70 years of age (inclusive) at time of enrollment - Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care - Confirmed diagnosis of symptomatic multiple myeloma. (Patients with multiple myeloma with secondary amyloidosis are eligible.) - Received at least two cycles of any regimen as initial systemic therapy for multiple myeloma and are within 2-16 months of the first dose of initial therapy - Eastern Cooperative Oncology Group (ECOG) performance status and/or other performance status 0, 1, or 2 - Adequate organ function as defined below: Absolute neutrophil count (ANC) >= 1,000 mm^3 Platelet count >= 75,000/mm^3; platelet transfusions to help patient meet eligibility criteria are not allowed within 7 days before study enrollment Total bilirubin <= 1.5 x upper limit of normal range (ULN) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <=3 x ULN Calculated creatinine clearance >= 30 mL/min - Women of childbearing potential must follow pregnancy testing requirements as outlined in the Revlimid REMS program material. This is defined as either committing to continued abstinence from heterosexual intercourse or beginning TWO acceptable methods of contraception (one highly effective method and one additional effective method AT THE SAME TIME) at least 28 days prior to the start of lenalidomide, for the duration of study participation, and for 28 days following the last dose of lenalidomide. Women of childbearing potential must also agree to ongoing pregnancy testing. - Men must agree to use a latex condom during sexual contact with a woman of childbearing potential even if they have had a successful vasectomy. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. - All study participants must be registered into the mandatory Revlimind REMS program and be willing to comply with its requirements. Per standard Revlimid REMS program requirements, all physicians who prescribe lenalidomide for research subjects enrolled into this trial, must be registered in, and must comply with, all requirements of the Revlimid REMS program. Exclusion Criteria Patients meeting any of the following exclusion criteria are not to be enrolled in the study: - Female patients who are lactating or have a positive serum pregnancy test during the screening period - Evidence of MM disease progression any time prior to enrollment. Progression from smoldering/asymptomatic MM to symptomatic MM is not exclusionary. - Tandem autologous transplantation - History of plasma cell leukemia or MM CNS involvement - Administration or planned administration of any other concomitant chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy which would be considered a treatment of multiple myeloma until Day +28 post-transplant through discontinuation from study. Patients may be on corticosteroids if they are being given for disorders other than multiple myeloma (e.g., adrenal insufficiency, rheumatoid arthritis, etc.) - Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol. - Prior organ transplant requiring immunosuppressive therapy - Active hepatitis A, B or C virus infection, or known human immunodeficiency virus (HIV) positive - Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent - Known GI disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib - Concurrent hematologic or non-hematologic malignancy requiring treatment (other than multiple myeloma and secondary amyloidosis) - Cardiac syncope, uncompensated NYHA Class 3 or 4 congestive heart failure, myocardial infarction within the previous six months, unstable angina pectoris, clinically significant repetitive ventricular arrhythmias despite antiarrhythmic treatment, severe orthostatic hypotension, or clinically important autonomic disease - Grade >= 3 peripheral neuropathy, or Grade 2 with pain on clinical examination during the screening period - Major surgery within 14 days prior to enrollment - Infection requiring systemic antibiotic therapy or other serious infection within 14 days prior to enrollment - Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days prior to enrollment and throughout the duration of this trial

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Ixazomib

Drug:
Lenalidomide

Dexamethasone


Locations

Country Name City State
United States Emory University - Winship Cancer Institute Atlanta Georgia
United States Ohio State University Comprehensive Cancer Center Columbus Ohio
United States Colorado Blood Cancer Institute Denver Colorado
United States Karmanos Cancer Institute Detroit Michigan
United States City of Hope Duarte California
United States Tennessee Oncology, PLLC Nashville Tennessee
United States Icahn School of Medicine at Mount Sinai New York New York
United States Mayo Clinic Rochester Minnesota
United States Washington University School of Medicine Saint Louis Missouri
United States University of California, San Francisco San Francisco California

Sponsors (3)

Lead Sponsor Collaborator
Washington University School of Medicine Millennium Pharmaceuticals, Inc., Multiple Myeloma Research Consortium

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Improvement in Minimal Residual Disease (MRD) For the purposes of this study, a patient will be considered as having minimal residual disease if a positive result (1x10E06) is obtained using the Adaptive Clonoseq MRD testing. After 4 cycles of IRD consolidation treatment (approximately Day 112 of consolidation treatment)
Secondary MRD-negative Rate After ASCT For the purposes of this study, a patient will be considered as having minimal residual disease if a positive result (1x10E06) is obtained using the Adaptive Clonoseq MRD testing Prior to beginning consolidation treatment (Day -28 to Day 0)
Secondary Toxicity of IRD Consolidation For the purposes of this study, toxicity will be defined as inability to receive 4 cycles of IRD consolidation due to toxicity. After 4 cycles of IRD consolidation treatment (approximately Day 112 of consolidation treatment)
Secondary Response Rate of IRD Consolidation For the purposes of this study, response rate is defined as the improvement in complete response rate. Response will be determined by the International Myeloma Working Group (IMWG) Uniform Response Criteria. After 4 cycles of IRD consolidation treatment (approximately Day 112 of consolidation treatment)
Secondary Progression-free Survival of IRD Consolidation Progression-free survival (PFS) will be defined as time from ASCT to progression, relapse, or death, whichever occurs first, and those event-free survivors will be censored at withdrawal or study closeout. Up to 18 months after completion of maintenance therapy (Up to 5 years after starting the study)
Secondary Overall Survival of IRD Consolidation Overall survival (OS) will be defined as time from ASCT to death due to any causes, and survivors will be censored at withdrawal or study closeout. Up to 18 months after completion of maintenance therapy (Up to 5 years after starting the study)
Secondary Compare Toxicity Between the Two Maintenance Arms The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting. 30 days after the completion of maintenance treatment (estimated to be Day 1125 of maintenance treatment)
Secondary Compare Response Rate Between the Two Maintenance Arms Response will be determined by the International Myeloma Working Group (IMWG) Uniform Response Criteria. Response includes stringent complete response (sCR) and complete response (CR).
sCR requires all of the following:
CR as defined below
Normal free light chain ratio (0.26-1.65)
Absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence
CR requires all of the following:
Disappearance of monoclonal protein by both protein electrophoresis and immunofixation studies from the blood and urine
If serum and urine monoclonal protein are unmeasurable, Normal free light chain ratio (0.26-1.65)
<5% plasma cells in the bone marrow
Disappearance of soft tissue plasmacytoma
Through completion of maintenance treatment (estimated to be day 1095 of maintenance treatment)
Secondary Compare Progression-free Survival Between the Two Maintenance Arms Progression-free survival (PFS) will be defined as time from ASCT to progression, relapse, or death, whichever occurs first, and those event-free survivors will be censored at withdrawal or study closeout. Up to 18 months after completion of maintenance therapy (Up to 5 years after starting the study)
Secondary Compare Overall Survival Between the Two Maintenance Arms Overall survival (OS) will be defined as time from ASCT to death due to any causes, and survivors will be censored at withdrawal or study closeout. Up to 18 months after completion of maintenance therapy (Up to 5 years after starting the study)
Secondary Rate of MRD-positive to MRD-negative Conversion Between the Two Maintenance Arms Cycle 13 Day 1 of maintenance treatment (Approximately Day 364 of maintenance treatment)
Secondary Association of Progression-free Survival With MRD-negativity Progression-free survival (PFS) will be defined as time from ASCT to progression, relapse, or death, whichever occurs first, and those event-free survivors will be censored at withdrawal or study closeout. Up to 18 months after completion of maintenance therapy (Up to 5 years after starting the study)
Secondary Association of Progression-free Survival With MRD-positivity Progression-free survival (PFS) will be defined as time from ASCT to progression, relapse, or death, whichever occurs first, and those event-free survivors will be censored at withdrawal or study closeout. Up to 18 months after completion of maintenance therapy (Up to 5 years after starting the study)
Secondary Association of Overall Survival With MRD-negativity Overall survival (OS) will be defined as time from ASCT to death due to any causes, and survivors will be censored at withdrawal or study closeout. Up to 18 months after completion of maintenance therapy (Up to 5 years after starting the study)
Secondary Association of Overall Survival With MRD-positivity Overall survival (OS) will be defined as time from ASCT to death due to any causes, and survivors will be censored at withdrawal or study closeout. Up to 18 months after completion of maintenance therapy (Up to 5 years after starting the study)
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1